Cured but breathless: the growing burden of DIILD in cancer survivors

IF 82.2 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-08-13 DOI:10.1038/s41571-025-01064-4

Jing-Xing Li, Wen-Chien Cheng

引用次数: 0

Abstract

Drug-induced interstitial lung disease (DIILD) is emerging as a hidden toll of modern oncology. Diagnosis of DIILD is confounded by non-specific symptoms and the absence of validated biomarkers, leaving clinicians to navigate heterogeneous, drug-specific guidelines. Herein, we discuss this predicament and advocate a shift from reactive management towards proactive survivorship.

查看原文本刊更多论文

治愈了却喘不过气来：癌症幸存者的DIILD负担越来越重

药物性间质性肺疾病（DIILD）正在成为现代肿瘤学中一种隐性疾病。DIILD的诊断因非特异性症状和缺乏有效的生物标志物而混淆，使临床医生无法驾驭异质性的药物特异性指南。在此，我们讨论了这一困境，并主张从被动管理向主动生存的转变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.